| First Author | Shioda N | Year | 2018 |
| Journal | Nat Med | Volume | 24 |
| Issue | 6 | Pages | 802-813 |
| PubMed ID | 29785027 | Mgi Jnum | J:271579 |
| Mgi Id | MGI:6278191 | Doi | 10.1038/s41591-018-0018-6 |
| Citation | Shioda N, et al. (2018) Targeting G-quadruplex DNA as cognitive function therapy for ATR-X syndrome. Nat Med 24(6):802-813 |
| abstractText | Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is caused by mutations in ATRX, which encodes a chromatin-remodeling protein. Genome-wide analyses in mouse and human cells indicate that ATRX tends to bind to G-rich sequences with a high potential to form G-quadruplexes. Here, we report that Atrx mutation induces aberrant upregulation of Xlr3b expression in the mouse brain, an outcome associated with neuronal pathogenesis displayed by ATR-X model mice. We show that ATRX normally binds to G-quadruplexes in CpG islands of the imprinted Xlr3b gene, regulating its expression by recruiting DNA methyltransferases. Xlr3b binds to dendritic mRNAs, and its overexpression inhibits dendritic transport of the mRNA encoding CaMKII-alpha, promoting synaptic dysfunction. Notably, treatment with 5-ALA, which is converted into G-quadruplex-binding metabolites, reduces RNA polymerase II recruitment and represses Xlr3b transcription in ATR-X model mice. 5-ALA treatment also rescues decreased synaptic plasticity and cognitive deficits seen in ATR-X model mice. Our findings suggest a potential therapeutic strategy to target G-quadruplexes and decrease cognitive impairment associated with ATR-X syndrome. |
